Modified GIP Analogues for Diabetes Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GIP analogues have a short in vivo half-life due to susceptibility to proteolysis, leading to reduced stability and efficacy as therapeutic agents for conditions like non-insulin dependent diabetes mellitus and obesity, and they produce fragments that act as receptor antagonists.
Innovation Solution
Development of peptide variants with specific amino acid modifications, such as substitution at positions 1, 2, and 3, and the use of PEGylation to enhance stability and plasma half-life while maintaining receptor binding affinity, thereby providing tighter control over plasma glucose levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If unmodified GIP is used as a therapeutic agent, then it can stimulate insulin secretion and lower plasma glucose, but it has a short in vivo half-life of about 2 minutes due to degradation by dipeptidyl peptidase IV
Solution Approach 1:
The patent modifies the amino acid sequence parameters of GIP by introducing cyclic amino acid residues at specific positions (1-3, 11-13, 40-42) to change the peptide's structural parameters. This structural modification prevents degradation by dipeptidyl peptidase IV, thereby extending the in vivo half-life from 2 minutes to several hours while maintaining insulinotropic activity
Solution Approach 2:
The patent creates a composite peptide structure by combining conventional amino acids with cyclic amino acid residues in a specific sequence. This composite structure integrates the beneficial properties of both standard peptide bonds and cyclic modifications, achieving enhanced stability and prolonged half-life while preserving biological activity
2Stability of the object's composition
If GIP analogues are modified to extend half-life, then stability and plasma half-life are improved, but the complexity of peptide synthesis and characterization increases
Solution Approach 1:
The patent applies cyclic modification only at specific local positions (1-3, 11-13, 40-42) rather than throughout the entire peptide sequence. This localized modification approach achieves the desired stability enhancement while minimizing the increase in synthesis complexity, as only specific residues need to be cyclically modified rather than the entire peptide
3Reliability
If GIP is used to enhance insulin secretion, then plasma glucose levels are lowered, but GIP fragments are produced that act as GIP receptor antagonists
Solution Approach 1:
The patent introduces cyclic amino acid residues at positions 1-3, 11-13, and 40-42 that preemptively prevent proteolytic cleavage at these locations. By protecting these specific positions from degradation, the cyclic modifications prevent the formation of harmful receptor antagonistic fragments before they can be generated, while preserving the active insulinotropic function
Data Source
Figure 1
AI summary
There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP- receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non- insulin dependent diabetes mellitus and obesity.